Fennec Pharmaceuticals (FENC) CFO receives 1,703-share stock award

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. reported that Chief Financial Officer Robert Andrade acquired 1,703 common shares on July 31, 2026 via a grant/award at a stated price of $0.0000 per share. A footnote explains these shares were released from restrictions on awards granted May 16, 2024 and March 28, 2025. After this release, Andrade directly holds 292,675 common shares.

Insider Trade Summary

Net Buyer: 1,703 shares

Net Buy 1 txn

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common shares F1	1,703	$0.00	$0.00

Holdings After Transaction: Common shares — 292,675 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.

Key Figures

Shares acquired: 1,703 common shares Transaction price per share: $0.0000 Shares held after transaction: 292,675 common shares

3 metrics

Shares acquired 1,703 common shares Grant/award acquisition on July 31, 2026

Transaction price per share $0.0000 Stated price for the grant/award acquisition

Shares held after transaction 292,675 common shares Direct holdings of Robert Andrade following the July 31, 2026 transaction

Key Terms

Grant, award, or other acquisition, released from restriction, Common shares

3 terms

Grant, award, or other acquisition financial

"Transaction code description is "Grant, award, or other acquisition" for these shares"

released from restriction financial

"Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025."

Common shares financial

"The security title for the reported transaction is listed as Common shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:05 PM Accepted by SEC EDGAR 08/03/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider share transaction did FENC report for CFO Robert Andrade?

FENNEC PHARMACEUTICALS INC. reported that CFO Robert Andrade acquired 1,703 common shares on July 31, 2026. The acquisition was coded as a grant, award, or other acquisition with a stated transaction price of $0.0000 per share, reflecting a non-cash share release.

How many FENC shares does CFO Robert Andrade hold after this transaction?

Following the July 31, 2026 transaction, CFO Robert Andrade directly holds 292,675 common shares of FENNEC PHARMACEUTICALS INC. This figure reflects his updated direct ownership position after the 1,703-share release from restriction reported in the Form 4 filing.

What is the origin of the 1,703 FENC shares released to the CFO?

The 1,703 common shares reported for CFO Robert Andrade represent shares released from restriction tied to prior equity awards. A footnote states they came from shares awarded on May 16, 2024 and March 28, 2025, which subsequently vested or became unrestricted.

Was the FENC CFO’s July 31, 2026 share acquisition under a Rule 10b5-1 plan?

The filing indicates the transaction was not made under a Rule 10b5-1 trading plan. The document-level 10b5-1 checkbox is marked as false, meaning the company did not affirm that this insider share acquisition occurred pursuant to a pre-arranged trading plan.

Did the July 31, 2026 FENC insider transaction involve derivative securities?

No. The reported transaction for CFO Robert Andrade involves non-derivative common shares only. The security title is listed as common shares, and the filing’s derivative section shows no derivative transactions, indicating the event was purely a release of previously awarded stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	07/31/2026		A		1,703	A	$0	292,675	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.

	/s/ Robert Andrade	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)